CRESCENT BIOPHARMA, INC. — Director's Dealing 2020

Mar 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2020-03-09

Reporting Person: JUNIUS DANIEL M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-09	Common Stock	P	20000	$3.40	Acquired	38000	Direct

Footnotes

F1: The Reporting Person purchased the securities on the open market at purchase prices ranging from $3.40 to $3.41 per share, with a weighted average purchase price of $3.40 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.